Home/Filings/4/0000950170-24-015185
4//SEC Filing

AFEYAN NOUBAR 4

Accession 0000950170-24-015185

CIK 0001770121other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:00 PM ET

Size

8.0 KB

Accession

0000950170-24-015185

Insider Transaction Report

Form 4
Period: 2024-02-12
Transactions
  • Purchase

    Pre-Funded Warrants to purchase Common Stock

    2024-02-12$5.50/sh+2,727,272$14,999,7232,727,272 total(indirect: By Flagship Pioneering Fund VII, L.P.)
    Exercise: $0.00From: 2024-02-12Common Stock (2,727,272 underlying)
AFEYAN NOUBAR
10% Owner
Transactions
  • Purchase

    Pre-Funded Warrants to purchase Common Stock

    2024-02-12$5.50/sh+2,727,272$14,999,7232,727,272 total(indirect: By Flagship Pioneering Fund VII, L.P.)
    Exercise: $0.00From: 2024-02-12Common Stock (2,727,272 underlying)
Footnotes (2)
  • [F1]On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.
  • [F2]Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Documents

1 file

Issuer

Sana Biotechnology, Inc.

CIK 0001770121

Entity typeother

Related Parties

1
  • filerCIK 0001222012

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:00 PM ET
Size
8.0 KB